about
Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from ten Phase I trials.Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure.Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology PatientsPopulation Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer
P50
description
researcher
@en
name
Diansong Zhou
@en
type
label
Diansong Zhou
@en
prefLabel
Diansong Zhou
@en
P31
P496
0000-0002-2673-1069